Study S001947

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira (REMIT IDegLira): A Randomized Controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03862716
Acronym: REMITiDegLira
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 159
Start: 2019-04-23
Primary completion: 2022-06-15
Lead sponsor: Population Health Research Institute
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:IDegLira; DRUG:insulin degludec; DRUG:Metformin; BEHAVIORAL:Lifestyle Therapy
Results posted: FALSE

Registered primary outcomes

Proportion of participants achieving drug-free diabetes remission [28 weeks after randomization]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011292	Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial. Punthakee Z, Diabetes, obesity & metabolism	2024	Randomized trial	PMID 39239702 DOI	cites ClinicalTrials.gov:NCT03862716